Fresh Equities
Offers
Learn
TELIX PHARMACEUTICALS LIMITED

INVESTOR PRESENTATION - TELIX PHARMACEUTICALS LIMITED

ASX:TLX

TELIX PHARMACEUTICALS LIMITED

Health Care

Telix Pharmaceuticals Limited (TLX) is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation" (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer.

Read more

Market Cap

457.10m

Price at Close

$1.8

4w avg. Volume

763.48k

4w avg. Turnover

$1.29m

Announcements
announcementt+2 movementdate
  • First patients dosed in Phase I study of APOMAB theranostic

    Progress Report

  • -

    20 Sep 2020

-

20 Sep 2020
  • Strategic Collaboration with Varian for Prostate Imaging

    Progress Report · Market sensitive

  • +5.85%

    02 Sep 2020

+5.85%

02 Sep 2020
  • IRE Distribution Partnership for Prostate Cancer Imaging

    Progress Report · Market sensitive

  • +3.64%

    31 Aug 2020

+3.64%

31 Aug 2020
  • FDA grants orphan drug designation for TLX102

    Progress Report · Market sensitive

  • +3.64%

    30 Aug 2020

+3.64%

30 Aug 2020
  • Half Year Shareholder Update

    Periodic Reports

  • +0.70%

    20 Aug 2020

+0.70%

20 Aug 2020
  • Report for half-year to 30 June 2020

    Periodic Reports · Market sensitive

  • +0.70%

    20 Aug 2020

+0.70%

20 Aug 2020
  • First patient dosed in renal cancer imaging study in Japan

    Progress Report

  • +3.33%

    17 Aug 2020

+3.33%

17 Aug 2020
  • Drug Master File for Glioblastoma Product Filed with FDA

    Progress Report

  • -1.47%

    10 Aug 2020

-1.47%

10 Aug 2020
  • Investor call - H1 Results and Company Update

    Periodic Reports

  • -1.47%

    10 Aug 2020

-1.47%

10 Aug 2020
  • Appendix 4C and Activities Report - June 2020 quarter

    Commitments test entity quarterly reports · Market sensitive

  • -1.54%

    26 Jul 2020

-1.54%

26 Jul 2020
Market Data

Current Price

$1.8

52WK HIGH

$1.95

52WK LOW

$0.755

1YR RETURN

+17.65%

1YR RETURN VS. SECTOR

-12.53%

90 DAY RETURN

+42.29%

ASX RANK

379

/2,019

SECTOR RANK

9

/47

SHARES OUTSTANDING

253.94m
ASX:TLX

TELIX PHARMACEUTICALS LIMITED

Health Care

Telix Pharmaceuticals Limited (TLX) is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or molecularly-targeted radiation" (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer.

Read more

Market Cap

457.10m

Price at Close

$1.8

4w avg. Volume

763.48k

4w avg. Turnover

$1.29m

ASX:TLX is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Support

Live Chat

Research
Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.